Multiple Comparisons of Repeated Measured Response: Issues of Assessment of Prolongation of QT Interval in Thorough QT Trials

被引:3
|
作者
Tsong, Yi [1 ]
Zhong, Jinglin [1 ]
机构
[1] US FDA, DBVI, Off Biostat, Off Translat Sci,Ctr Drug Evaluat & Res, Silver Spring, MD USA
关键词
Multiple comparisons; QT interval; Repeated measured responses; STATISTICAL ISSUES; CONFIDENCE-BOUNDS;
D O I
10.1080/10543400903582018
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The primary objective of a thorough QT clinical trial is to demonstrate the lack of QT prolongation induced by the test treatment. The ICH E14 guidance defined drug-induced prolongation of QT interval as evidenced by an upper bound of the 95% one-sided confidence interval around the mean effect on QTc of 10ms. Furthermore, it defined a negative thorough QT/QTc study as one in which the upper bound of the 95% one-sided confidence interval for the largest time-matched mean effect of the drug on the QTc interval excludes 10ms. Conventionally, this objective is tested with the intersection-union test by testing the mean difference between the test treatment and placebo of QTc changes from baseline at each of the matched time points. The multiple-comparison nature of the test leads to higher false positive rate when comparisons are made repeatedly at multiple time points. Many approaches have been proposed in the last 5 years in order to improve the efficiency of the test. In this article, we survey and discuss some of the approaches.
引用
收藏
页码:613 / 623
页数:11
相关论文
共 50 条
  • [1] Multiple Comparisons of Repeatedly Measured Response: Issues of Validation Testing in Thorough QT/QTc Clinical Trials
    Tsong, Yi
    Yan, Lihan K.
    Zhong, Jinglin
    Nie, Lei
    Zhang, Joanne
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2010, 20 (03) : 654 - 664
  • [2] Pharmacogenetic issues in thorough QT trials
    Judson, Richard S.
    Salisbury, Benjamin A.
    Reed, Carol R.
    Ackerman, Michael J.
    [J]. MOLECULAR DIAGNOSIS & THERAPY, 2006, 10 (03) : 153 - 162
  • [3] Pharmacogenetic Issues in Thorough QT Trials
    Richard S. Judson
    Benjamin A. Salisbury
    Carol R. Reed
    Michael J. Ackerman
    [J]. Molecular Diagnosis & Therapy, 2006, 10 : 153 - 162
  • [4] Drug-induced QT prolongation when QT interval is measured in each of the 12 ECG leads in men and women in a thorough QT study
    Panicker, Gopi Krishna
    Salvi, Vaibhav
    Karnad, Dilip R.
    Chakraborty, Saikat
    Manohar, Deepak
    Lokhandwala, Yash
    Kothari, Snehal
    [J]. JOURNAL OF ELECTROCARDIOLOGY, 2014, 47 (02) : 155 - 157
  • [5] The assessment of QT/QTc interval prolongation in clinical trials: A regulatory perspective
    Strnadova, C
    [J]. DRUG INFORMATION JOURNAL, 2005, 39 (04): : 407 - 433
  • [6] The Assessment of QT/QTc Interval Prolongation in Clinical Trials: A Regulatory Perspective
    Colette Strnadova
    [J]. Drug information journal : DIJ / Drug Information Association, 2005, 39 : 407 - 435
  • [7] Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter?
    Shah, Rashmi R.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (02) : 347 - 358
  • [8] The preclinical assessment of the risk for QT interval prolongation
    Champeroux, P
    Martel, E
    Vannier, C
    Blanc, V
    Leguennec, JY
    Fowler, J
    Richard, S
    [J]. THERAPIE, 2000, 55 (01): : 101 - 109
  • [10] Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice
    Isbister, Geoffrey K.
    Page, Colin B.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 76 (01) : 48 - 57